Research is still required to evidence nutritional intake in GLP-1 RA users, and to subsequently inform dietary recommendations that are specific for this population
M.MalnicG.et al
Dosing mistakes are the most common, and most preventable, problem in peptide research
FDAs 2025 Increase in Warning Letters on Compounded Drug Advertising In recent remarks at the Food and Drug Law Institutes Enforcement, Litigation, and Compliance Conference, the director of the Office of Compliance within FDAs Center for Drug Evaluation and Research's (CDER) noted that 22% of warning letters that CDER issued in fiscal year (FY) 2025 were sent to telehealth platforms and other entities related to claims made regarding compounded drug products, including compounded GLP-1s
Participants were randomized to receive tirzepatide at doses of 5 mg, 10 mg, or 15 mg weekly, or placebo, for 176 weeks (over three years), followed by a 17-week off-treatment period